Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Gemini Ascendant: Axsome questions, get good phase III answers in MDD ...
Axsome will begin trial this year in MDD with daytime sleepiness
Axsome Advances MDD Drug, Explores New ADHD Treatment - BioSpace
Axsome Therapeutics’ MDD Auvelity treatment gets green light from FDA
Axsome Seeks Approval for MDD Drug - PharmaLive
Axsome Opens CLARITY Trial As Solriamfetol Targets Underserved MDD Patients
Axsome Therapeutics wins FDA for novel antidepressant Auvelity
Axsome Therapeutics, Inc. on LinkedIn: #depression #mdd
Axsome Therapeutics Announces FDA Approval of AUVELITY(TM)
Axsome Shows Positive Phase 2 Data in Major Depressive Disorder ...
Axsome Therapeutics Announces FDA Approval of AUVELITY ...
Axsome Therapeutics: SYMPHONY Catalyst Unlocking (NASDAQ:AXSM ...
Axsome - Foster Display Group
Biotech Values : >>> Axsome Therapeutics : There...
U.S. FDA Approves Axsome Therapeutics’ SYMBRAVO™ (meloxicam and ...
Axsome Therapeutics Priced For Perfection Ahead Of Auvelity's Alzheimer ...
Axsome Therapeutics: Expect Victory In 2022 (NASDAQ:AXSM) | Seeking Alpha
Axsome Triumphs Over Major Depressive Disorder With Auvelity
Axsome Therapeutics Announces FDA Acceptance and Priority Review of New ...
Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for ...
Axsome Therapeutics Wins FDA Nod for Auvelity in Alzheimer’s Agitation ...
Axsome Advances Toward FDA Filing For Drug To Treat Narcolepsy
MAESTrO: Axsome Therapeutics announces FDA approval of Auvelity, the ...
Axsome Therapeutics Jumps On FDA Priority Review For Alzheimer's ...
Here's Why Axsome Therapeutics Stock Rocketed 813% in the First Half of ...
Major Depressive Disorder (MDD) - Axsome Therapeutics
Este médico nacido en Haití creó un negocio de 6,000 mdd desarrollando ...
Axsome Therapeutics: A Promising Biotech Play in Central Nervous System ...
Axsome soars on FDA approval of oral depression drug Auvelity | The ...
Axsome rebounds to win FDA approval of depression drug | BioPharma Dive
FDA approves Axsome Therapeutics’ oral antidepressant Auvelity
Axsome Therapeutics Emerges as a High-Growth Contender in Neurological ...
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol ...
FDA Approves Axsome Therapeutics’ Symbravo for Migraine with or without ...
Axsome Therapeutics Announces Positive Results from the COMET-SI Trial ...
A quick fix for depression? Axsome Therapeutics develops fast-acting ...
AXSM STOCK GOT CRUSHED - AXSOME HAS ISSUES WITH FDA DELAYS AND ...
Axsome Therapeutics (AXSM) – Two Readouts in 1Q | JaguarAnalytics
Revisiting Axsome After Its 800% Year-To-Date Rally
Axsome has Major Upcoming Catalysts, Find Out Here! | Avise Analytics
Axsome Therapeutics Q1 2026 Earnings Review: Gains Mystify Me, But Can ...
Axsome Therapeutics Clocks Better Than Expected Q1 Sales, Depression ...
Axsome Therapeutics: A Momentum-Driven Journey in CNS Therapies
Axsome Completes Phase 3 Clinical Program with AXS-05 in Alzheimer ...
Axsome wins FDA priority review for Auvelity in Alzheimer’s disease ...
Axsome Therapeutics Announces Positive Phase 3 Results for Reboxetine ...
Axsome Therapeutics Stock Rallies After FDA Gives Breakthrough Status ...
Axsome Therapeutics – a new depression-treatment
Axsome Therapeutics Announces FDA Acceptance and Priority
Got $10,000? Axsome Therapeutics Could Be a Mental‑Health Moonshot by ...
Axsome Therapeutics Announces FDA Approval of AUVELITY™, the First and ...
Why Axsome Therapeutics Stock Rocketed Higher to End 2025 | The Motley Fool
The Play On Axsome Therapeutics (NASDAQ:AXSM) | Seeking Alpha
Axsome Therapeutics, Inc. - ROE
Axsome Therapeutics, Inc. on LinkedIn: #acnp2023 #depression # ...
Axsome Q1 2025 slides: 62% revenue growth as CNS portfolio expands By ...
Axsome Therapeutics Unveils Mixed Results In ADHD Treatment. Axsome ...
Axsome Shares Up 20% in a Month: How Should You Play the Stock?
Axsome (AXSM) Starts Late-Stage Study of Migraine Drug AXS-07
Why Axsome Therapeutics (AXSM) Stock Surged Over 40% In One Day : r ...
Axsome Stock Dives Again On Second Big Drug Failure In A Week ...
Axsome Therapeutics' phase 3 trial shows significant symptom ...
Axsome Therapeutics, Inc. (AXSM) BCG Matrix Analysis – DCFmodeling.com
What are Mission Vision & Core Values of Axsome Company? – Pestel ...
Examples of (a) high MDD and (b) low MDD | Download Scientific Diagram
Axsome Therapeutics: A Conditional Buy Built On SG&A Discipline (NASDAQ ...
Axsome Presents Q1 Results, Advances in Sleep Medicine Pipeline | Sleep ...
Neuroscience Education Institute (NEI) 2024 Congress – Axsome Medical ...
Axsome Therapeutics’ AXS-05 Receives FDA Priority Review for Alzheimer ...
Axsome Stock Surges: FDA Approval Boosts Migraine Drug!
Axsome to Submit Narcolepsy Drug Candidate AXS-12 to FDA in 2025’s ...
Axsome Therapeutics launches antidepressant in crowded market, route to ...
DAMPs cross-talk interpretation of MDD mechanisms | Science Advances
Migraine Treatment: US FDA approves Axsome Therapeutics' migraine drug ...
Axsome Q2 2025 slides: revenue surges 72% YoY, pipeline advances on ...
Join Axsome Therapeutics and become part of a team that is developing ...
Slide 10
GRAPHIC
Axsome's Auvelity becomes first FDA-approved oral NMDA for major ...
Axsome's Auvelity wins FDA expansion for Alzheimer's agitation
This Month in Psychopharmacology
FDA approves Axsome’s fast-acting treatment for major depression
Axsome's Q4 Surprise: Record Revenues, Job Market Boost, and Global ...
Slide 28
Northern California Psychiatric Society (NCPS) 63rd Annual Meeting and ...
Slide 29
Axsome's depression drug Auvelity sustains improvements in symptoms in ...
Understanding Major Depressive Disorder (MDD) – AltAhar
Axsome's Depression Drug Gets Breakthrough Therapy Status | Investing.com
AXSM Q1 2026 Earnings Report on 5/4/2026
American College of Neuropsychopharmacology (ACNP) 63rd Annual Meeting ...
Axsome’s Wait Pays Off With Broad Auvelity Label For Major Depression
Our third quarter results highlight our continued commercial ...
FDA approves Symbravo (meloxicam and rizatriptan) for the acute ...
What are the Porter's Five Forces of Axsome?
US FDA approves Axsome's drug for Alzheimer's-related agitation
